Oncologie

A Phase II of TAXOL® (Paclitaxel) over 3 hours in 192 platinum pre-treated patients for ovarian carcinoma

ECCO8Lhomme C, Guastalla J-P, Dauplat J, Ferrera J-M, Oberling F, Vennin P, Pouillart P, Fumoleau P, Kerbrat P, Tubiana N, Heron J-F, Bugat R, Bachelot T, Schreinerova M, Fleury J, Namer M, Dufour P, Dieras V, Soler-Michel P, Pruvot I, Chanez M-A, Garet F, Chazard M, Pellae-Cosset B.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Use of Digital Health Technology to Enable Drug Development
Oncologie

Use of Digital Health Technology to Enable Drug Development

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study 
Oncologie

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study 

Primary efficacy analysis of a phase II study of neoadjuvant Bevacizumab, chemotherapy, and Trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY 2 study
Oncologie

Primary efficacy analysis of a phase II study of neoadjuvant Bevacizumab, chemotherapy, and Trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY 2 study